Simplify Logo
Zeiss

Zeiss

Corporate venture capital for deep-tech startups

Account Manager - Managed Vision Care

Full-Time
$96.6k - $120.8k/yr

+ Performance Bonus

Senior
Gloucester Township, NJ, USA+1 more

More locations: Princeton, NJ, USA

In Person
Company Does Not Provide H1B Sponsorship

About the job

Requirements
  • A minimum of 5 years of relevant experience developing and leading commercial business initiatives and/or account management in the optical or healthcare industry.
  • Managed Vision Care experience, including familiarity with reimbursement models, is preferred.
Responsibilities
  • Meet and exceed annual revenue targets as communicated by the Senior Director or Head of Managed Vision Care.
  • Develop, maintain, and expand relationships with key stakeholders in assigned Managed Vision Care accounts, including formulary, operations, customer service, information technology, and marketing teams, to increase ZEISS product and laboratory access and value for eye care professional providers and members.
  • Understand and champion Managed Vision Care strategy and business goals in support of the company's product strategy and roadmap.
  • Develop, plan, and implement product initiatives, promotions, training, education, and value-added programs that achieve business goals, expand product access, and grow share of wallet.
  • Initiate, organize, and facilitate business activities between the company and Managed Vision Care teams, including quarterly and annual business reviews and business plans.
  • Provide direction and alignment on Managed Vision Care key performance indicators and facilitate internal communication with relevant cross-functional departments, including laboratory operations, customer service, information technology, and marketing.
  • Lead monthly operational business reviews with Managed Vision Care partners, identify opportunities, and develop plans to improve the end-to-end customer journey and increase eye care professional provider access to products.
  • Lead monthly formulary review meetings with assigned Managed Vision Care accounts and the Product Management team; monitor, track, and take corrective action as necessary.
  • Prepare sales and volume forecasts to support budget and demand-planning cycles.
  • Develop and deliver high-impact, customer-relevant, and financially supported proposals.
  • Gather and analyze competitive data and communicate findings and recommendations.
  • Act as the company's internal expert on the Managed Vision Care business model, formulary, and operating model, including revenue and profit drivers for patients, eye care professionals, and laboratories.
  • Translate the advantages and benefits of company products and services to Managed Vision Care formulary teams in partnership with Product Management to support appropriate coverage.
  • Analyze Managed Vision Care reimbursement schedules and value propositions from patient, eye care professional, and laboratory perspectives; quantify upgrade paths and business-case opportunities.
  • Partner with Learning and Development to develop and deliver Managed Vision Care training for sales teams and external customers, and deliver customer training where appropriate.
  • Provide timely and continuous input to the Senior Director or Head of Managed Vision Care to ensure plans are on track.
  • Perform necessary functions to ensure sales meet objectives.
  • Follow safety standards and report safety concerns to leadership.
  • Follow compliance requirements and report concerns to leadership.
Desired Qualifications
  • Managed Vision Care experience, including familiarity with reimbursement models.

About the company

ZEISS Ventures is the corporate venture capital arm of the ZEISS Group, investing in deep-tech startups in Information Technology, Industrial Tech, MedTech, and Life Sciences. It backs early-stage companies at pre-Series A to Series A with typical investments of $1–5 million. The fund provides capital and tailored funding solutions, leveraging ZEISS’s global network and optics/optoelectronics expertise to support portfolio companies. Its goal is to accelerate the development of new technologies and business models that complement ZEISS’s portfolio while actively engaging with external innovation.

Company Size

1,001-5,000

Company Stage

Growth Equity (Non-Venture Capital)

Total Funding

$67.7M

Headquarters

Oberkochen, Germany

Founded

2001

Get referred to Zeiss

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ZEISS Ventures led SeeTrue's €2.2 million round on 2026-08-05, reinforcing eye-tracking leadership.
  • ZEISS backed Maculaser and Custom Surgical in 2026, deepening ophthalmology innovation pipelines.
  • ZEISS launched Otus ML 1.4/35, Panoptes 65, and DuraVision Plus in 2026.

What critics are saying

  • ZEISS Meditec plans up to 1,000 job cuts through 2028/29 after 5.7% revenue decline.
  • ProfitUp requires over €150m restructuring costs, signaling weak margins and execution strain.
  • If ophthalmology turnaround fails, ZEISS Meditec drags group cash flow and venture appetite.

What makes Zeiss unique

  • ZEISS Ventures backs deep-tech tied to ZEISS optics, medtech, and industrial workflows.
  • ZEISS brings distribution, engineering, and clinical validation to early startups like Custom Surgical.
  • ZEISS spans lenses, microscopy, and eye care, creating cross-selling across adjacent markets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Paid Vacation

Performance Bonus

Company News

Yahoo Finance
Aug 27th, 2026
ZEISS launches DORC EVA NEXUS cataract system at ESCRS in London

ZEISS Medical Technology has launched a cataract-only configuration of its DORC EVA NEXUS ophthalmic surgical system. The system features a cataract grade selection with up to four programmable presets, allowing surgeons to optimise phaco, aspiration, and irrigation settings for each surgical step. The solution includes VacuFlow VTi pump, SMART IOP, and EVA EQUIPHACO technologies, designed to provide streamlined performance, stability, and control during procedures. It integrates with the ZEISS Cataract Workflow portfolio. The system debuted at the European Society of Cataract and Refractive Surgeons congress in London. It will become available in select European countries from September 2026, with global rollout pending regulatory approvals. The technology expands ZEISS's existing EVA NEXUS platform, which previously focused on retina workflows.

PR Newswire
Aug 19th, 2026
ZEISS CLINIC 360 receives FDA clearance for cloud-based ophthalmic data management software

ZEISS Medical Technology announced FDA 510(k) clearance for ZEISS CLINIC 360, a cloud-based software solution that aggregates ophthalmic clinical data and provides advanced analytics. The browser-based platform combines diagnostic and medical data into a comprehensive patient view, helping clinicians evaluate disease progression and support treatment decisions. The solution integrates data from DICOM-enabled diagnostic devices, including ZEISS's CIRRUS, CLARUS and HFA systems, as well as third-party devices. It features disease-based summaries, interactive analysis tools, and collaboration capabilities through ZEISS Collaborative Care. ZEISS CLINIC 360 will be available in the US in early autumn 2026 on a subscription basis with low upfront costs. The platform complements ZEISS FORUM, the company's on-premise data management system, giving providers flexibility in choosing their preferred infrastructure approach.

ZEISS
Aug 5th, 2026
ZEISS leads $2.5M investment in SeeTrue Technologies for miniaturised eye-tracking tech

ZEISS Ventures led a €2.2 million investment round in SeeTrue Technologies, a Finnish deep-tech company developing miniaturised eye-tracking technology. The funding will accelerate commercialisation of SeeTrue's ultra-low-power eye-sensing architecture for next-generation interfaces in smart optical systems and eyewear. SeeTrue's proprietary technology combines miniaturised sensing hardware with optimised embedded processing, enabling scalable eye-sensing capabilities with low power consumption and small hardware footprint. The technology supports gaze-based interaction and attention-aware computing across healthcare, industrial, and smart eyewear applications. The investment round includes participation from Superhero Capital and North Karelia Growth Fund, managed by Redstone Nordics. Founded in 2018 and based in Joensuu, Finland, SeeTrue develops ultra-miniature eye-tracking technology for medical optical systems, vision care, and smart wearables.

PR Newswire
Jun 11th, 2026
ZEISS completes early implantations of AT LUCIA toric 721P intraocular lens

ZEISS Medical Technology has announced successful early clinical implantations of its AT LUCIA toric 721P intraocular lens, designed to treat cataracts whilst correcting astigmatism. The company is conducting an early-access clinical trial with experienced surgeons across six European countries. The lens combines an aspheric bitoric optic with a patented non-constant aberration design on a fully preloaded, hydrophobic platform. Surgeons have reported positive early impressions, highlighting the lens's precision, stability and surgical handling. Currently CE marked, the AT LUCIA toric 721P will be showcased at the International Congress of German Ophthalmic Surgery in Nuremberg from 18–20 June 2026. The lens is expected to be commercially available in select European countries later this year.

ZEISS
May 28th, 2026
ZEISS invests in Maculaser to advance temperature-controlled retinal laser therapy

ZEISS Ventures has invested in Maculaser, a Finnish medtech company developing temperature-controlled retinal laser therapy, through a funding round co-led with M2care. The investment will support clinical development of the company's personalized treatment for retinal diseases. Founded in 2020 and based on research from Aalto University, Maculaser has developed patented technology that provides real-time temperature control during laser treatment. The non-damaging approach activates natural cellular defence mechanisms, targeting affected retinal areas early to delay or prevent progression of age-related macular degeneration and diabetic maculopathy. The technology aims to shift retinal care from managing late-stage damage to proactive vision preservation, offering an outpatient procedure that integrates into regular eye care. Maculaser plans to bring the treatment into clinical practice to benefit millions of patients worldwide.